Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 160
Filtrar
1.
Medicine (Baltimore) ; 98(41): e17501, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31593119

RESUMO

BACKGROUND: Traditional treatment of functional dyspepsia (FD) is unsatisfactory in a subgroup of patients with FD, and the potential role of antidepressant medications also has not been definitely clarified. To provide more evidence for future optimal practice recommendations, we reviewed a 1-year clinical database of antidepressant agents applied in outpatients with FD. METHODS: Clinical presentations, treatment course, and outcomes were determined by chart review of patients referring to the functional gastrointestinal disorders specialist clinic. One hundred thirty patients with FD were included for further analysis. RESULTS: Patients were treated with different antidepressant drugs according to individual symptoms. The most commonly used drugs were flupenthixol melitracen and fluoxetine. Improvement and complete remission occurred in 93.8% and 54.6% of patients, respectively. There was a trend toward superior outcome for citalopram compared to sulpiride and mirtazapine in overall analysis. Meanwhile, regimens containing fluoxetine had significant increased remission rate compared to any other antidepressant regimens in postprandial distress syndrome subgroup analysis. Furthermore, older patients were more likely to achieve remission. However, sex and symptom duration were not associated with symptom remission. Finally, 11.5% of patients experienced adverse events. CONCLUSIONS: This retrospective cohort study indicated that small dose antidepressant therapy, especially citalopram and fluoxetine, is an effective and well tolerated treatment option for refractory FD.


Assuntos
Antracenos/uso terapêutico , Dispepsia/tratamento farmacológico , Fluoxetina/uso terapêutico , Flupentixol/uso terapêutico , Antracenos/efeitos adversos , Antidepressivos/efeitos adversos , Antidepressivos/uso terapêutico , China/epidemiologia , Citalopram/uso terapêutico , Combinação de Medicamentos , Dispepsia/diagnóstico , Feminino , Fluoxetina/efeitos adversos , Flupentixol/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Mirtazapina/uso terapêutico , Período Pós-Prandial , Indução de Remissão , Estudos Retrospectivos , Resultado do Tratamento
2.
Drug Des Devel Ther ; 13: 3331-3342, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31571834

RESUMO

Purpose: A fixed-dose combination (FDC) tablet of melitracen/flupentixol has been widely used for depression. The purpose of this study was to assess the safety profile and the relative bioavailability of two FDC products containing 10 mg melitracen and 0.5 mg flupentixol from two different manufacturers, in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. Methods: The study was designed as a single-dose, randomized, open-label, 2-period crossover study under fasted or fed conditions in healthy Chinese subjects. Twenty-four subjects (16 men and 8 women) were selected for fasted study, and another 24 cases (16 men and 8 women) were in fed study. Each subject was randomized at the beginning to receive either a single dose of the reference FDC or the test FDC tablet during the first period. Following two-week washout period, all subjects received the alternate formulation during the second period. Blood samples were collected up to 144 hrs after administration. Pharmacokinetic parameters, including Cmax, Tmax, AUC0-t, AUC0-∞, t½, CL/F, and Vd/F were acquired based on the time versus concentration profiles. Then, the geometric mean ratios (GMR) and corresponding 90% CIs were calculated for the determination of bioequivalence analysis. Safety assessment included changes in vital signs and laboratory tests, physical examination findings, and incidence or reports of adverse events (AEs). Results: The present study has clearly indicated the test and the reference FDC products are bioequivalent in terms of rate and extent of drug absorption. GMR of Cmax, AUC0-t, and AUC0-∞ for both flupentixol and melitracen between the two formulation FDC products, and corresponding 90% CIs, were all within the range of 80% to 125% under fasted or fed conditions. Both the test and the reference FDC products indicated good tolerance in all volunteers. Chinese Clinical Trials Registry identifier: CTR20171256.


Assuntos
Antracenos/farmacocinética , Antidepressivos/farmacocinética , Flupentixol/farmacocinética , Adulto , Antracenos/administração & dosagem , Antracenos/efeitos adversos , Antidepressivos/administração & dosagem , Antidepressivos/efeitos adversos , Área Sob a Curva , China , Estudos Cross-Over , Combinação de Medicamentos , Jejum , Feminino , Flupentixol/administração & dosagem , Flupentixol/efeitos adversos , Voluntários Saudáveis , Humanos , Masculino , Comprimidos , Equivalência Terapêutica , Adulto Jovem
3.
Metab Brain Dis ; 34(6): 1679-1687, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31422510

RESUMO

First-episode psychosis (FEP) patients are more sensitive to neuroleptic side-effects such as hyperprolactinemia. We examined the prolactin levels of previously minimally treated patients with first episode schizophrenia over their first year of treatment with flupenthixol decanoate and the relationship between prolactin levels, gender and clinical features of schizophrenia. Prolactin levels were assessed at three monthly intervals in 126 patients with first-episode schizophrenia in a single-site study conducted over 12 months during treatment with flupenthixol decanoate according to a fixed protocol. The mean prolactin level for the total sample was 11.91 ng/ml (standard deviation [SD]15.52) at baseline. Women had higher levels of prolactin than men at month 3, 6 and 12, reaching statistical significance at month 12 (p = 0.02). At 12 months more women than men had hyperprolactinemia (defined as more than 20 ng/ml for males, and as more than 25 ng/ml for females (p = 0.007). Using a mixed effect model, there was a significant association between prolactin change scores over 12 months and gender (p = 0.025) as well as Positive and Negative Syndrome Scale (PANSS) total scores (p = 0.001). In addition female gender (p = 0.04) and age (p = 0.02) correlated with the risk of hyperprolactinemia as categorical variable. In this study treatment with flupenthixol decanoate was associated with relatively low levels of hyperprolactinemia, likely owing to flupenthixol's relatively atypical mode of action, as well as to the low doses used in our study. We found an inverse correlation between total PANSS scores and prolactin levels, which could support the suggested theory of prolactin having antipsychotic properties. Our study confirms the importance of gender on the prolactin raising effects of antipsychotic treatment.


Assuntos
Flupentixol/análogos & derivados , Hiperprolactinemia/induzido quimicamente , Propafenona/sangue , Esquizofrenia/tratamento farmacológico , Tranquilizantes/uso terapêutico , Adolescente , Adulto , Fatores Etários , Feminino , Flupentixol/efeitos adversos , Flupentixol/uso terapêutico , Humanos , Masculino , Esquizofrenia/sangue , Fatores Sexuais , Tranquilizantes/efeitos adversos , Resultado do Tratamento , Adulto Jovem
4.
Medicine (Baltimore) ; 98(2): e14064, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30633208

RESUMO

BACKGROUND: There are many trials on the combination of Pinaverium bromide (PB) and Flupentixol-melitracen (FM) in the treatment of diarrhea-type irritable bowel syndrome (IBS-D), but the sample sizes are small, and the research conclusions are inconsistent. Thus, a meta-analysis was performed, aiming to evaluate the efficacy and safety of this combination therapy in patients with IBS-D. METHODS: A systematic literature search was conducted in 7 databases covering the period up to July 2018 to identify randomized controlled trials (RCTs) of PB combined with FM versus PB alone for IBS-D. The primary outcome was the total symptom relief rate. The other outcomes were the adverse events rate, HAMA/SAS score, and HAMD/SDS score. The methodological quality of the RCTs was assessed independently using 6 criteria according to the Cochrane Collaboration. All data were analyzed using Review Manager 5.3. RESULTS: Fifteen RCTs with 1487 participants were identified from 2005 to 2018. Compared with PB alone, 15 RCTs showed significant effects of PB plus FM in terms of improved symptom relief in patients with IBS-D (n = 1487, OR = 5.17, 95%CI, 3.79-7.07, P < .00001). Eleven RCTs reported adverse effects in both the PB plus FM and PB groups, there was no statistically significant difference in the adverse events rate between the 2 groups (n = 1207, OR = 2.91, 95%CI, 0.91-9.28, P = 0.07). Two RCTs and 3 RCTs reported HAMA and HAMD scores respectively, and 3 RCTs reported both SAS and SDS scores. After treatment, the above scores in the PB plus FM group were significantly lower than the PB group (all P < .01). However, the trials were deemed to have a medium risk of bias. CONCLUSIONS: The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use. However, the conclusions still need to be verified by conducting more large-scale and high-quality RCTs.


Assuntos
Antracenos/uso terapêutico , Flupentixol/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Síndrome do Intestino Irritável/tratamento farmacológico , Morfolinas/uso terapêutico , Antracenos/efeitos adversos , Diarreia/tratamento farmacológico , Combinação de Medicamentos , Quimioterapia Combinada , Flupentixol/efeitos adversos , Fármacos Gastrointestinais/efeitos adversos , Humanos , Morfolinas/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto
5.
Int Ophthalmol ; 38(4): 1769-1773, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28676993

RESUMO

AIM: To report the first case report of an association between flupentixol and crystalline retinopathy. STUDY DESIGN: Observational, Case report. CASE REPORT: We report a case of crystalline retinopathy in a 36-year-old female who was suffering from depression and being treated with tablet flupentixol in a cumulative dose of 4380 mg over two years. Fundus examination of both eyes showed multiple, discrete, yellowish white refractile intraretinal deposits over the macula and peripapillary region, located in the inner retina as shown by OCT. CONCLUSION: We propose regular retinal evaluation in patients with chronic flupentixol intake and larger studies to establish causal relationship between flupentixol and crystalline retinopathy.


Assuntos
Antipsicóticos/efeitos adversos , Cristalinas/metabolismo , Flupentixol/efeitos adversos , Doenças Retinianas/induzido quimicamente , Feminino , Humanos , Doenças Retinianas/patologia , Transtornos da Visão/induzido quimicamente
6.
Early Interv Psychiatry ; 10(1): 54-62, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24690088

RESUMO

AIM: To assess the feasibility and effectiveness of depot antipsychotic (flupenthixol decanoate) combined with an assertive monitoring programme (AMP) in first-episode schizophrenia. METHODS: This was a prospective, non-comparative, longitudinal study conducted over 12 months assessing patient acceptance, adherence, outcome in domains of psychopathology, functionality and quality of life, and tolerability. RESULTS: Of 207 participants, 149 (72%) completed 12 months of treatment. Acceptance of and adherence to depot was good. Treatment response was achieved by 170 (82%) participants and remission by 124 (60%). Thirty-three (19%) responders relapsed and 10 (5%) participants met a priori criteria for treatment resistance. Treatment was generally well tolerated. CONCLUSIONS: Combination of depot antipsychotic with an AMP may be an effective and safe intervention in early phases of schizophrenia, and may be particularly suitable for resource-constrained settings.


Assuntos
Serviços Comunitários de Saúde Mental/métodos , Flupentixol/análogos & derivados , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Adulto , Antipsicóticos/uso terapêutico , Preparações de Ação Retardada/efeitos adversos , Preparações de Ação Retardada/uso terapêutico , Países em Desenvolvimento , Feminino , Flupentixol/efeitos adversos , Flupentixol/uso terapêutico , Humanos , Masculino , Adesão à Medicação , Aceitação pelo Paciente de Cuidados de Saúde , Qualidade de Vida , Resultado do Tratamento
8.
Psychiatry Res ; 233(2): 186-93, 2015 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-26184461

RESUMO

We investigated whether morphological brain changes occurred in brain regions associated with body-weight homeostasis during acute antipsychotic treatment, and if so, whether they were related to changes in body mass and metabolic profile. Twenty-two antipsychotic-naive patients with first-episode schizophrenia received either risperidone long acting injection or flupenthixol decanoate over 13 weeks and were compared by structural MRI with 23 matched healthy volunteers at weeks 0, 4 and 13. Images were reconstructed using freesurfer fully-automated whole brain segmentation. The ventral diencephalon and prefrontal cortex were selected to represent the homeostatic and hedonic food intake regulatory systems respectively. Body mass was measured at weeks 0, 7 and 13 and fasting glucose and lipid profiles at weeks 0 and 13. Linear mixed effect models indicated significant group(⁎)time interactions for the ventral diencephalon volumes bilaterally. Ventral diencephalon volume reduction was strongly correlated bilaterally with body mass increase and HDL-cholesterol reductions, and unilaterally with blood glucose elevation. There were no significant changes in prefrontal cortical thickness. These findings implicate the ventral diencephalon, of which the hypothalamus is the main component, in the acute adipogenic and dyslipidaemic effects of antipsychotic medication.


Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Índice de Massa Corporal , Encéfalo/efeitos dos fármacos , Encéfalo/fisiopatologia , Ingestão de Alimentos/efeitos dos fármacos , Ingestão de Alimentos/fisiologia , Flupentixol/análogos & derivados , Interpretação de Imagem Assistida por Computador/métodos , Imagem por Ressonância Magnética/métodos , Risperidona/efeitos adversos , Esquizofrenia/tratamento farmacológico , Esquizofrenia/fisiopatologia , Adolescente , Adulto , Preparações de Ação Retardada , Método Duplo-Cego , Feminino , Flupentixol/administração & dosagem , Flupentixol/efeitos adversos , Humanos , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Risperidona/administração & dosagem , África do Sul , Adulto Jovem
9.
World J Gastroenterol ; 21(15): 4652-9, 2015 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-25914475

RESUMO

AIM: To explore whether clinician-patient communication affects adherence to psychoactive drugs in functional dyspepsia (FD) patients with psychological symptoms. METHODS: A total of 262 FD patients with psychological symptoms were randomly assigned to four groups. The patients in Groups 1-3 were given flupentixol-melitracen (FM) plus omeprazole treatment. Those in Group 1 received explanations of both the psychological and gastrointestinal (GI) mechanisms of the generation of FD symptoms and the effects of FM. In Group 2, only the psychological mechanisms were emphasized. The patients in Group 3 were not given an explanation for the prescription of FM. Those in Group 4 were given omeprazole alone. The primary endpoints of this study were compliance rate and compliance index to FM in Groups 1-3. Survival analyses were also conducted. The secondary end points were dyspepsia and psychological symptom improvement in Groups 1-4. The correlations between the compliance indices and the reductions in dyspepsia and psychological symptom scores were also evaluated in Groups 1-3. RESULTS: After 8 wk of treatment, the compliance rates were 67.7% in Group 1, 42.4% in Group 2 and 47.7% in Group 3 (Group 1 vs Group 2, P = 0.006; Group 1 vs Group 3, P = 0.033). The compliance index (Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.024) with the FM regimen was significantly higher in Group 1 than in Groups 2 and 3. The survival analysis revealed that the patients in Group 1 exhibited a significantly higher compliance rate than Groups 2 and 3 (Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.018). The improvement in dyspepsia (Group 1 vs Group 2, P < 0.05; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01) and psychological symptom scores (anxiety: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01; depression: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.01; Group 1 vs Group 4, P < 0.01) in Group 1 were greater than those in Groups 2-4. The compliance indices were positively correlated with the reduction in symptom scores in Groups 1-3. CONCLUSION: Appropriate clinician-patient communication regarding the reasons for prescribing psychoactive drugs that emphasizes both the psychological and GI mechanisms might improve adherence to FM in patients with FD.


Assuntos
Antracenos/uso terapêutico , Atitude do Pessoal de Saúde , Comunicação , Dispepsia/tratamento farmacológico , Flupentixol/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Conhecimentos, Atitudes e Prática em Saúde , Adesão à Medicação , Relações Médico-Paciente , Psicotrópicos/uso terapêutico , Adulto , Idoso , Antracenos/efeitos adversos , China , Combinação de Medicamentos , Dispepsia/diagnóstico , Dispepsia/psicologia , Feminino , Flupentixol/efeitos adversos , Fármacos Gastrointestinais/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Omeprazol/uso terapêutico , Inibidores da Bomba de Prótons/uso terapêutico , Psicotrópicos/efeitos adversos , Indução de Remissão , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento
10.
Eur Psychiatry ; 30(2): 277-83, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25577186

RESUMO

OBJECTIVES: To assess changes in body mass and metabolic profiles in patients with first-episode schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of the effects. METHODS: We investigated the changes in body mass, fasting blood glucose and lipids in 107 largely antipsychotic naïve, first-episode schizophrenia patients who were treated according to a standard algorithm with long-acting injectable flupenthixol decanoate over 12 months. RESULTS: Eighty-three (78%) participants completed the 12 months of treatment, and 104 (97%) received 100% of the prescribed injections during their participation. There were significant increases in BMI (P<.0001), waist circumference (P=0.0006) and triglycerides (P=0.03) and decrease in HDL (P=0.005), while systolic (P=0.7) and diastolic blood pressure (P=0.8), LDL (P=0.1), cholesterol (P=0.3), and glucose (P=0.9) values did not change over time. The triglyceride: HDL ratio increased by 91%. Change in BMI was only correlated with change in triglycerides (P=.008). The only significant predictor of BMI increase was non-substance abuse (P=.002). CONCLUSIONS: The risks of weight gain and metabolic syndrome associated with antipsychotic treatment in first-episode schizophrenia are not restricted to second generation antipsychotics. This is a global problem, and developing communities may be particularly susceptible.


Assuntos
Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Glicemia/metabolismo , Índice de Massa Corporal , Colesterol/sangue , Flupentixol/análogos & derivados , Síndrome Metabólica/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Triglicerídeos/sangue , Adulto , Biomarcadores/sangue , Estudos de Coortes , Feminino , Flupentixol/administração & dosagem , Flupentixol/efeitos adversos , Humanos , Masculino , Síndrome Metabólica/sangue , Metaboloma , Esquizofrenia/sangue , África do Sul , Ganho de Peso/efeitos dos fármacos
11.
J Gambl Stud ; 31(1): 295-7, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24356928

RESUMO

Pathological gambling is defined as inappropriate, persistent, and maladaptive gambling behaviour. It is a non-pharmacological addiction classified as an impulse control disorder. However, pathological gambling has been associated with dopamine agonist use. Here we report of a 28-year-old man with a first major depressive episode and a post-traumatic stress disorder who has been treated with a combination of the serotonine/noradrenaline reuptake inhibitor duloxetine and the tricyclic antidepressant maprotiline. The administration of antipsychotic flupentixole (up to 7 mg) turned this slight online poker gambler into an excessive gambler. Only after the discontinuation of the antidopaminergic agents and the switch to bupropion did this gambling behaviour stop which suggests a causal relationship between dopamine antagonists and pathological gambling.


Assuntos
Comportamento Aditivo/induzido quimicamente , Antagonistas de Dopamina/efeitos adversos , Flupentixol/efeitos adversos , Jogo de Azar/induzido quimicamente , Adulto , Comportamento Aditivo/psicologia , Transtorno Depressivo Maior/complicações , Transtorno Depressivo Maior/tratamento farmacológico , Antagonistas de Dopamina/administração & dosagem , Flupentixol/administração & dosagem , Jogo de Azar/psicologia , Humanos , Masculino , Transtornos de Estresse Pós-Traumáticos/complicações , Transtornos de Estresse Pós-Traumáticos/tratamento farmacológico
12.
Cochrane Database Syst Rev ; (9): CD009227, 2014 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-25177834

RESUMO

BACKGROUND: Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency antipsychotic drugs are sometimes perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects. OBJECTIVES: To review the effects in clinical response of flupenthixol and low-potency antipsychotics for people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (July 2010). SELECTION CRITERIA: Randomised controlled trials that compared flupenthixol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For continuous data, we calculated mean differences (MD) based on a random-effects model. MAIN RESULTS: The review currently includes one randomised trial from mainland China with 153 participants that lasted two months and compared flupenthixol with chlorpromazine. The exact methods of sequence generation and allocation concealment were not reported, and medication was provided in an open manner. There were no data on the outcomes that we had a priori selected for a 'Summary of findings' table.There was no significant difference between flupenthixol and chlorpromazine in the participants' general mental state at endpoint as measured by the Brief Psychiatric Rating Scale (BPRS) total score (1 randomised controlled trial (RCT), n = 153, MD 2.20 95% confidence interval (CI) -1.25 to 5.65). Chlorpromazine was associated with significantly less dizziness (1 RCT, n = 153, MD 0.12 95% CI 0.01 to 0.23); dystonia (1 RCT, n = 153, MD 0.29 95% CI 0.13 to 0.45); unsteady gait (1 RCT, n = 153, MD 0.46 95% CI 0.28 to 0.64); reduced facial expression (1 RCT, n = 153, MD 0.27 95% CI 0.09 to 0.45); restlessness (1 RCT, n = 153, MD 0.69 95% CI 0.45 to 0.93); rigidity (elbow) (1 RCT, n = 153, MD 0.48 95% CI 0.28 to 0.68); and tremor (1 RCT, n = 153, MD 0.56 95% CI 0.34 to 0.78). Chlorpromazine produced more dryness of mouth than flupenthixol (1 RCT, n = 153, MD -0.14 95% CI -0.25 to -0.03). AUTHORS' CONCLUSIONS: The evidence base of flupenthixol versus low-potency first-generation antipsychotics is currently restricted to one randomised comparison with chlorpromazine. The few reported data do not suggest a difference in efficacy, but flupenthixol appeared to produce more movement disorders and dizziness, while chlorpromazine was associated with the anticholinergic side effect - dryness of mouth. More trials are needed to make conclusions about the relative effects of flupenthixol and low-potency antipsychotics.


Assuntos
Antipsicóticos/uso terapêutico , Clorpromazina/uso terapêutico , Flupentixol/uso terapêutico , Esquizofrenia/tratamento farmacológico , Acatisia Induzida por Medicamentos/etiologia , Antipsicóticos/efeitos adversos , Clorpromazina/efeitos adversos , Flupentixol/efeitos adversos , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Xerostomia/induzido quimicamente
13.
J Gastroenterol Hepatol ; 29(6): 1200-6, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24955450

RESUMO

BACKGROUND AND AIM: This study was designed to demonstrate the safety and efficacy of esomeprazole combined with flupentixol/melitracen for the treatment of gastroesophageal reflux disease (GERD) patients with emotional disorders. METHODS Two hundred eighty-nine GERD patients with emotional disorders were divided randomly into two groups: group 1 received esomeprazole only (monotherapy) and group 2 received esomeprazole and flupentixol/melitracen (combination therapy). The patients' GERD questionnaire (GerdQ) and hospital anxiety and depression (HAD) scores were obtained before and after treatment. Changes in the scores, rates of symptom remission, and adverse effects were compared between the two groups. RESULTS: After 2 weeks of treatment, the average decrease in GerdQ score in the combination group (4.04 ± 2.34) was significantly greater than that in the monotherapy group (3.34 ± 2.74; P < 0.05). Significant differences between the two groups were also found for changes in HAD anxiety scores (5.45 ± 2.41 vs 3.34 ± 2.43, P < 0.05), depression scores (5.47 ± 2.47 vs 3.00 ± 3.28, P < 0.05), and anxiety-depression scores (5.20 ± 2.71 vs 3.60 ± 2.56, P < 0.05). The remission of symptoms (eructation, abdominal pain, anorexia, and other accompanying symptoms) in the combination group was significantly better than that in the monotherapy group, and no significant difference in the incidence of adverse events was observed between the two groups. CONCLUSIONS: The combination therapy has better efficacy than the monotherapy in improving the symptoms of gastroesophageal reflux in patients with emotional disorders. In addition, this combination treatment is safe, with a low incidence of adverse events.


Assuntos
Sintomas Afetivos/complicações , Antracenos/administração & dosagem , Esomeprazol/administração & dosagem , Flupentixol/administração & dosagem , Refluxo Gastroesofágico/complicações , Refluxo Gastroesofágico/tratamento farmacológico , Adulto , Antracenos/efeitos adversos , Ansiedade , Depressão , Combinação de Medicamentos , Quimioterapia Combinada , Esomeprazol/efeitos adversos , Feminino , Flupentixol/efeitos adversos , Refluxo Gastroesofágico/psicologia , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários , Resultado do Tratamento
14.
Eur Arch Psychiatry Clin Neurosci ; 264(2): 131-41, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23835526

RESUMO

This study compares the first-generation antipsychotic (FGA) flupentixol to haloperidol and common second-generation antipsychotics (SGAs) as to drug utilization and severe adverse drug reactions (ADRs) in clinical treatment of schizophrenia inpatients using data from the drug safety program Arzneimittelsicherheit in der Psychiatrie (AMSP). AMSP drug utilization and reported ADR data were analyzed. Type and frequency of severe ADRs attributed to flupentixol were compared with haloperidol, clozapine, olanzapine, quetiapine, risperidone and amisulpride in a total of 56,861 schizophrenia inpatients exposed to these drugs. In spite of increasing prescription of SGAs, flupentixol was consistently used in schizophrenic inpatients (about 5 %) over time. Reporting rates of severe ADR ranged from 0.38 to 1.20 % for the individual antipsychotics (drugs imputed alone); flupentixol ranked lowest. The type of ADR differed considerably; as to severe EPMS, flupentixol (0.27 %), such as risperidone (0.28 %), held an intermediate position between haloperidol/amisulpride (0.55/0.52 %) and olanzapine/quetiapine (<0.1 %). The study is a heuristic approach, not a confirmatory test. Flupentixol has a stable place in the treatment of schizophrenia in spite of the introduction of different SGAs. Comparative ADR profiles suggest an intermediate position between FGAs and SGAs for flupentixol in clinical practice.


Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/classificação , Flupentixol/efeitos adversos , Esquizofrenia/tratamento farmacológico , Feminino , Humanos , Masculino , Observação , Vigilância de Produtos Comercializados , Escalas de Graduação Psiquiátrica , Fatores de Tempo
16.
Int Clin Psychopharmacol ; 28(5): 283-5, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23820335

RESUMO

Little is known about the role of psychopharmacological treatment and course of illness in patients diagnosed with a paranoid personality disorder. This short communication provides a naturalistic study of a psychiatric hospital case series. Fifteen consecutive patients were retrospectively studied. The Clinical Global Impression was rated at first admission, at last psychiatric contact, and after a 6-week observation period with or without antipsychotic treatment. During psychiatric admissions, three patients improved markedly, eight showed only minor changes, and four worsened. In total, seven patients had been administered any antipsychotic medication. The median duration of treatment was 15 weeks (range 4 days-328 weeks). No major adverse effects were noted. Among patients with sixth-week observations available, four had received antipsychotics; they appeared to improve considerably compared with six patients who had not received antipsychotics. Although the findings should be interpreted with caution, they support the notion of the disorder being a relatively chronic condition, although antipsychotics appeared to be safe and possibly had an effect in the short term.


Assuntos
Antipsicóticos/uso terapêutico , Transtorno da Personalidade Paranoide/tratamento farmacológico , Adulto , Antipsicóticos/efeitos adversos , Estudos de Coortes , Terapia Combinada/efeitos adversos , Dinamarca , Feminino , Flupentixol/efeitos adversos , Flupentixol/uso terapêutico , Seguimentos , Hospitais Psiquiátricos , Humanos , Masculino , Pessoa de Meia-Idade , Terapia Ambiental , Transtorno da Personalidade Paranoide/terapia , Escalas de Graduação Psiquiátrica , Psicoterapia de Grupo , Estudos Retrospectivos , Resultado do Tratamento
17.
Prev Med ; 57 Suppl: S50-3, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23337566

RESUMO

OBJECTIVE: The objective of this study is to determine the prevalence of metabolic syndrome among schizophrenia patients receiving antipsychotic monotherapy in Malaysia. METHOD: A cross-sectional study was conducted at multiple centres between June 2008 and September 2011. Two hundred and five patients who fulfilled the DSM IV-TR diagnostic criteria for schizophrenia and who had been on antipsychotic medication for at least one year, were screened for metabolic syndrome. Patients receiving a mood stabilizer were excluded from the study. Metabolic syndrome was defined by using the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Treatment Panel III (ATP III) modified for Asian waist circumference. RESULTS: In the first-generation antipsychotic (FGA) group, the highest prevalence of metabolic syndrome was among patients treated with trifluoperazine and flupenthixol decanoate (66.7% each). For the second-generation antipsychotic (SGA) group, the highest prevalence of metabolic syndrome was among patients treated with clozapine (66.7%). The component with the highest prevalence in metabolic syndrome was waist circumference in both FGA and SGA groups except for aripiprazole in SGA. CONCLUSION: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in Malaysia was very high. Intervention measures are urgently needed to combat these problems.


Assuntos
Antipsicóticos/uso terapêutico , Síndrome Metabólica/epidemiologia , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/efeitos adversos , Aripiprazol , Clozapina/efeitos adversos , Clozapina/uso terapêutico , Estudos Transversais , Feminino , Flupentixol/efeitos adversos , Flupentixol/uso terapêutico , Humanos , Malásia/epidemiologia , Masculino , Síndrome Metabólica/induzido quimicamente , Síndrome Metabólica/etiologia , Pessoa de Meia-Idade , Piperazinas/efeitos adversos , Piperazinas/uso terapêutico , Quinolonas/efeitos adversos , Quinolonas/uso terapêutico , Esquizofrenia/complicações , Trifluoperazina/efeitos adversos , Trifluoperazina/uso terapêutico , Circunferência da Cintura , Adulto Jovem
20.
J Psychopharmacol ; 24(5): 649-56, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-18832434

RESUMO

This was a double blind, placebo-controlled, 4-way cross-over study in 12 healthy volunteer subjects of the acute effects of three drugs each of which are used in the clinic to treat some forms of anxiety: propranolol 40 mg, hydroxyzine 25 mg, flupentixol 0.5 mg and placebo. Each test session consisted of inhalation of air for 20 min, 10-min rest, inhalation of CO2 7.5% for 20 min, 10-min rest, followed by a single vital capacity inhalation of 35% CO2. The CO2 7.5% was administered at peak drug effect. Subjective effects were measured using Visual Analogue Scales (VAS), the Panic Symptom Inventory and the Generalised Anxiety Disorder Assessment inventory. Twelve subjects participated (eight men), with a mean age of 25.9 years. The expected subjective effects of CO2 were seen and these were significantly different from effects of peak air. However, there were no statistically significant differences between the drugs or between drugs and placebo, indeed there was a trend for some VAS anxiety scores to be higher than placebo in the drug groups. There were some significant differences in cardiovascular responses to CO2, with propranolol significantly decreasing heart rate and flupentixol increasing blood pressure when compared with placebo. The lack of subjective anxiolytic actions of the three drugs contrasts with our previous findings with acute benzodiazepines and chronic selective serotonin reuptake inhibitor administration. It may be that prolonged treatment with these agents would be required to show anxiolytic effects, although it may also be that their efficacy is insufficient to be demonstrated in this model. The lack of anxiolytic actions of propranolol, despite a significant reduction in heart rate, is a further support for a central action of CO2 to produce anxiety.


Assuntos
Ansiolíticos/administração & dosagem , Ansiedade/tratamento farmacológico , Dióxido de Carbono/toxicidade , Administração por Inalação , Adulto , Ansiolíticos/efeitos adversos , Ansiolíticos/farmacologia , Ansiolíticos/uso terapêutico , Ansiedade/induzido quimicamente , Ansiedade/fisiopatologia , Nível de Alerta/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Dióxido de Carbono/fisiologia , Sistema Cardiovascular/efeitos dos fármacos , Estudos Cross-Over , Método Duplo-Cego , Flupentixol/administração & dosagem , Flupentixol/efeitos adversos , Flupentixol/farmacologia , Flupentixol/uso terapêutico , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hidroxizina/administração & dosagem , Hidroxizina/efeitos adversos , Hidroxizina/farmacologia , Hidroxizina/uso terapêutico , Masculino , Propranolol/administração & dosagem , Propranolol/efeitos adversos , Propranolol/farmacologia , Propranolol/uso terapêutico , Inquéritos e Questionários , Capacidade Vital , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA